THE API POWDER DIARIES

“The existing problem has uncovered some structural weaknesses in the EU’s medicines offer chain and also a significant dependence on non-EU nations around the world for active pharmaceutical ingredients,” Kyriakides reported. She suggested that offer chain concerns be resolved within an EU pharmaceutical technique expected to be launched by